Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.

Liu HB, Urbanavicius D, Tan P, Spencer A, Dear AE.

Int J Oncol. 2014 Oct;45(4):1742-8. doi: 10.3892/ijo.2014.2555. Epub 2014 Jul 22.

PMID:
25051119
[PubMed - in process]
2.

The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.

Liu HB, Mayes PA, Perlmutter P, McKendrick JJ, Dear AE.

Int J Oncol. 2011 May;38(5):1421-5. doi: 10.3892/ijo.2011.914. Epub 2011 Jan 20.

PMID:
21253674
[PubMed - indexed for MEDLINE]
3.

The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression.

Liu HB, Voso MT, Gumiero D, Duong J, McKendrick JJ, Dear AE.

Int J Oncol. 2009 Feb;34(2):573-9.

PMID:
19148494
[PubMed - indexed for MEDLINE]
4.

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A.

Blood Cancer J. 2014 Jan 10;4:e170. doi: 10.1038/bcj.2013.68.

PMID:
24413064
[PubMed]
Free PMC Article
5.

5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.

Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF.

Leuk Res. 2006 Jan;30(1):69-76. Epub 2005 Jul 25.

PMID:
16043219
[PubMed - indexed for MEDLINE]
6.

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.

Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N.

Cancer. 2008 Oct 1;113(7):1596-604. doi: 10.1002/cncr.23789.

PMID:
18720364
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE.

Blood. 2009 Sep 24;114(13):2764-73. doi: 10.1182/blood-2009-02-203547. Epub 2009 Jun 22.

PMID:
19546476
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1.

DiGiuseppe JA, Kastan MB, Weng LJ, Gore SD.

In Vivo. 1999 Jan-Feb;13(1):1-6.

PMID:
10218124
[PubMed - indexed for MEDLINE]
11.

5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.

Schmelz K, Wagner M, Dörken B, Tamm I.

Int J Cancer. 2005 May 1;114(5):683-95.

PMID:
15609309
[PubMed - indexed for MEDLINE]
12.

Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.

Nishioka C, Ikezoe T, Yang J, Udaka K, Yokoyama A.

Leuk Res. 2011 Jul;35(7):932-9. doi: 10.1016/j.leukres.2011.04.004. Epub 2011 May 7.

PMID:
21550660
[PubMed - indexed for MEDLINE]
13.

Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF.

Exp Hematol. 2007 Feb;35(2):263-73.

PMID:
17258075
[PubMed - indexed for MEDLINE]
14.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

PMID:
20507806
[PubMed - indexed for MEDLINE]
Free Article
15.

Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.

Kanno S, Maeda N, Tomizawa A, Yomogida S, Katoh T, Ishikawa M.

Int J Oncol. 2012 Sep;41(3):862-8. doi: 10.3892/ijo.2012.1507. Epub 2012 Jun 6.

PMID:
22684370
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

Quintás-Cardama A, Santos FP, Garcia-Manero G.

Leukemia. 2011 Feb;25(2):226-35. doi: 10.1038/leu.2010.276. Epub 2010 Nov 30. Review.

PMID:
21116282
[PubMed - indexed for MEDLINE]
17.

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

Vigna E, Recchia AG, Madeo A, Gentile M, Bossio S, Mazzone C, Lucia E, Morabito L, Gigliotti V, Stefano LD, Caruso N, Servillo P, Franzese S, Fimognari F, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Apr;20(4):465-93. doi: 10.1517/13543784.2011.559164. Epub 2011 Mar 8. Review.

PMID:
21381982
[PubMed - indexed for MEDLINE]
18.

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.

Maiso P, Colado E, Ocio EM, Garayoa M, Martín J, Atadja P, Pandiella A, San-Miguel JF.

Leukemia. 2009 Dec;23(12):2265-74. doi: 10.1038/leu.2009.182. Epub 2009 Oct 8.

PMID:
19812608
[PubMed - indexed for MEDLINE]
19.

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C.

Blood. 2010 Sep 16;116(11):1908-18. doi: 10.1182/blood-2009-11-249474. Epub 2010 Jun 8.

PMID:
20530795
[PubMed - indexed for MEDLINE]
Free Article
20.

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.

Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G, Paolini S, Martinelli G, Martelli AM, Cocco L.

Leukemia. 2011 Feb;25(2):271-80. doi: 10.1038/leu.2010.266. Epub 2010 Nov 26.

PMID:
21109771
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk